Innovative Treatment Otolith Labs develops a non-invasive wearable device utilizing Vestibular Resonance Therapy (nVRT) to treat chronic vertigo, addressing a significant unmet need for over 11 million Americans suffering from vestibular disorders.

Strong Funding Support With a successful Series A funding of $20 million led by Morningside Ventures, Otolith Labs demonstrates solid investor confidence and potential for rapid product development and market entry.

Regulatory Recognition Receiving FDA Breakthrough Device Designation highlights the clinical efficacy and innovation of Otolith’s technology, streamlining pathways for commercialization and expanding market opportunities.

Growing Leadership Recent appointment of a Chief Clinical Officer and ongoing team expansion indicate strategic focus on clinical validation and Regulatory navigation, essential for sales growth in healthcare and medical device markets.

Market Potential With estimated revenues between $10M and $25M and a focus on prescription devices for vestibular conditions, Otolith Labs presents significant sales opportunities within the neurological and otolaryngology healthcare segments.